Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy.

Dose-dependent PR interval prolongation has been reported in preclinical studies of lacosamide (LCM), a recently U.S. Food and Drug Administration (FDA)-approved antiepileptic drug (AED).